UCLA SPORE in Prostate Cancer

UCLA SPORE 在前列腺癌中的应用

• 批准号: 10000832
• 负责人: ROBERT E REITER
• 金额: $ 144.91万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10000832
• 关键词: Androgen Receptor; Antibodies; Area; Bioinformatics; Biometry; CAR T cell therapy; California; Cancer Patient; Castration; Cell Nucleus; Chemistry; Cities; Clinic; Clinical; Development; Diagnosis; Discipline; Disease; Drug Targeting; Environment; FDA approved; FOLH1 gene; Fat-Restricted Diet; Fostering; Funding; Goals; Human; Image; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; Laboratory Research; Lymphoma; MAP Kinase Gene; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Measurable; Morbidity - disease rate; Nanotechnology; Neoplasm Metastasis; Neurosecretory Systems; Omega-3 Fatty Acids; Outcome; PTEN gene; Pathology; Pathway interactions; Play; Prostate; Prostate Cancer therapy; Radiology Specialty; Reproduction spores; Research; Research Personnel; Research Support; Resistance; Scientist; Signal Transduction; Sister; Specimen; Talents; Technology; Translational Research; Translations; Work; antibody engineering; anticancer research; biomarker-driven; cancer stem cell; career development; combat; data management; design; drug development; human capital; improved; innovation; men; mortality; neuroendocrine phenotype; new technology; novel; novel strategies; outcome forecast; pre-clinical; prevent; programs; prostate cancer metastasis; prostate stem cell antigen; radioligand; research and development; stem cell biology; targeted treatment; therapy resistant; translational impact; translational research program

OVERALL SUMMARY/ABSTRACT The UCLA Prostate Cancer SPORE is a multidisciplinary and translational research program focused on the development of new and innovative approaches for improving the diagnosis, prognosis, and treatment of prostate cancer patients. The program’s reach includes collaborating investigators at local institutions such as Cedars Sinai and City of Hope in order to accelerate the goal of combating prostate cancer. A particular strength of the UCLA Prostate Cancer SPORE has been its ability to leverage institutional and NCI support to attract new human capital, technology, and ideas to the field of prostate cancer. Examples of these discoveries include: (1) the development of both the androgen receptor (AR) super-antagonists enzalutamide and apalutamide, (2) the discovery of the putative human prostate cancer stem cell of origin and its association with emergence of the lethal neuroendocrine phenotype, (3) the translation of novel engineered antibodies targeting Prostate Stem Cell Antigen (PSCA) to the clinic to target, treat and image prostate (and pancreatic) cancer, (4) the elucidation of signaling cross-talk between the PTEN/PI3K, AR, and ras/MAPK pathways in castrate resistant and treatment resistant prostate cancer (CRPC), and (5) the demonstration that a low fat diet supplemented with omega-3 fatty acids has measurable effects on prostate cancer and its mechanism of action. The overall goal of this competitive renewal application is to continue to apply the diversity of talent on the UCLA campus, its sister institutions and other institutions in Southern California to the critical and evolving translational challenges in the field of prostate cancer. To achieve the long-term objectives and goals of our program, the Specific Aims of the UCLA SPORE in Prostate Cancer are: (1) to perform high-impact translational research focused on some of the major challenges in the field of prostate cancer such as cancer metastasis, castration resistance, and treatment resistance, (2) to provide organizational infrastructure and novel technologies designed specifically to support the translational research objectives of the SPORE such as administrative, fiscal, and statistical support, and (3) to develop new prostate cancer researchers and research areas to advance translational research in prostate cancer through supporting innovative research in critical areas, pilot developmental research, and career development in prostate cancer research. Through these aims, UCLA Prostate Cancer SPORE can continue to promote significant and novel discoveries with potential major impact on men with prostate cancer.

总体总结/摘要 加州大学洛杉矶分校前列腺癌孢子是一个多学科和转化研究计划，重点是 开发新的和创新的方法，以改善前列腺疾病的诊断、预后和治疗 癌症患者。该计划的范围包括与当地机构的合作调查人员，如雪松 西奈半岛和希望之城，以加快防治前列腺癌的目标。一种特殊的力量 加州大学洛杉矶分校前列腺癌孢子一直有能力利用机构和NCI的支持，以吸引新的人类 资金、技术、理念等投入到前列腺癌领域。这些发现的例子包括：（1） 雄激素受体（AR）超级拮抗剂Enzalutamide和apalutamide的开发，（2） 假定的人类前列腺癌起源干细胞的发现及其与前列腺癌发生的关系 致死性神经内分泌表型，（3）靶向前列腺干细胞的新型工程抗体的翻译 抗原（PSCA）用于临床靶向、治疗和成像前列腺癌（和胰腺癌），（4）阐明 在去势抵抗和治疗中PTEN/PI 3 K、AR和ras/MAPK通路之间的信号传导串扰 抵抗性前列腺癌（CRPC），和（5）证明补充omega-3脂肪酸的低脂肪饮食 前列腺素对前列腺癌及其作用机制具有可测量的作用。 这种竞争性的更新应用程序的总体目标是继续适用于加州大学洛杉矶分校的人才的多样性 校园，其姐妹机构和其他机构在南加州的关键和不断发展的翻译 前列腺癌的治疗方法为了实现我们计划的长期目标， 加州大学洛杉矶分校前列腺癌研究中心的具体目标是：（1）进行高影响力的转化研究 关注前列腺癌领域的一些主要挑战，如癌症转移、去势 阻力和治疗阻力，（2）提供组织基础设施和新技术 专门设计用于支持SPORE的转化研究目标，如行政，财政， 和统计支持，以及（3）开发新的前列腺癌研究人员和研究领域，以推进 通过支持关键领域的创新研究，试点前列腺癌的转化研究 发展研究和前列腺癌研究的职业发展。通过这些目标，UCLA 前列腺癌孢子可以继续促进具有潜在重大影响的重大和新颖的发现 前列腺癌的男性患者。